GLP-2 Drug Makes Intestines Grow Longer in Short Bowel Syndrome — And Growth Persists After Stopping
GLP-2 analogues (teduglutide and apraglutide) induced lasting intestinal length growth in neonatal short-bowel piglets that persisted or increased after treatment cessation, unlike mucosal changes that faded.
Quick Facts
What This Study Found
GLP-2 analogues increased intestinal length by day 7 (p=0.005), maintained (teduglutide) or further increased (apraglutide) at day 14 after cessation (p<0.001). Mucosal adaptation (villus hyperplasia) was not durable after treatment cessation.
Key Numbers
P=0.005 length at day 7; P<0.001 at day 14; villus hyperplasia P=0.081 at day 14; teduglutide 0.05mg/kg BID; apraglutide 5mg/kg twice weekly
How They Did This
Neonatal short-bowel piglet model. Three groups: saline control, teduglutide (0.05mg/kg twice daily × 7 days), apraglutide (5mg/kg twice weekly × 7 days). Endpoints at day 7 and day 14 (7 days after cessation). Intestinal length, weight, histology, and mucosal gene expression measured.
Why This Research Matters
Lasting intestinal growth means GLP-2 treatment courses could permanently improve gut capacity in infants with short bowel syndrome, potentially freeing them from lifelong IV nutrition — a transformative outcome.
The Bigger Picture
This distinguishes two types of intestinal response to GLP-2: temporary mucosal changes and lasting structural growth. For neonates, who have natural growth potential, GLP-2 drugs could catalyze permanent intestinal lengthening — potentially curative for short bowel syndrome.
What This Study Doesn't Tell Us
Neonatal piglet model — human neonatal intestine may respond differently. Short observation period (14 days). Only two GLP-2 analogues tested. Molecular mechanisms of lasting growth not identified. Long-term outcomes and functional absorption capacity not assessed.
Questions This Raises
- ?How long does the intestinal length growth persist beyond 14 days?
- ?Does longer-acting apraglutide produce greater permanent lengthening than teduglutide?
- ?Can GLP-2 treatment during a critical neonatal window cure short bowel syndrome?
Trust & Context
- Key Stat:
- Growth persists after stopping Intestinal length growth from GLP-2 treatment was maintained or increased 7 days after stopping treatment (p<0.001) — suggesting lasting structural change, not temporary stimulation
- Evidence Grade:
- Moderate evidence: well-designed neonatal animal model with controlled comparison between two GLP-2 analogues, but limited to piglets and short follow-up.
- Study Age:
- Published 2021. Apraglutide and teduglutide continue in clinical development for short bowel syndrome.
- Original Title:
- Durability of Linear Small-Intestinal Growth Following Treatment Discontinuation of Long-Acting Glucagon-Like Peptide 2 (GLP-2) Analogues.
- Published In:
- JPEN. Journal of parenteral and enteral nutrition, 45(7), 1466-1474 (2021)
- Authors:
- Hinchliffe, Tierah, Pauline, Mirielle L, Wizzard, Pamela R, Nation, Patrick N, Brubaker, Patricia, Campbell, Jhenielle R, Kim, Yunji, Dimitriadou, Violetta, Wales, Paul W, Turner, Justine M
- Database ID:
- RPEP-05444
Evidence Hierarchy
Frequently Asked Questions
Can GLP-2 drugs grow more intestine?
Yes — in this neonatal piglet study, GLP-2 drugs physically lengthened the intestine, and this growth persisted even after stopping treatment. For babies with short bowel syndrome who depend on IV feeding, this could mean more gut to absorb nutrients normally.
What is the difference between teduglutide and apraglutide?
Both are GLP-2 receptor agonists, but apraglutide has a longer half-life requiring only twice-weekly dosing. In this study, apraglutide showed continued intestinal growth even after stopping treatment, possibly due to its longer duration of action.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05444APA
Hinchliffe, Tierah; Pauline, Mirielle L; Wizzard, Pamela R; Nation, Patrick N; Brubaker, Patricia; Campbell, Jhenielle R; Kim, Yunji; Dimitriadou, Violetta; Wales, Paul W; Turner, Justine M. (2021). Durability of Linear Small-Intestinal Growth Following Treatment Discontinuation of Long-Acting Glucagon-Like Peptide 2 (GLP-2) Analogues.. JPEN. Journal of parenteral and enteral nutrition, 45(7), 1466-1474. https://doi.org/10.1002/jpen.2053
MLA
Hinchliffe, Tierah, et al. "Durability of Linear Small-Intestinal Growth Following Treatment Discontinuation of Long-Acting Glucagon-Like Peptide 2 (GLP-2) Analogues.." JPEN. Journal of parenteral and enteral nutrition, 2021. https://doi.org/10.1002/jpen.2053
RethinkPeptides
RethinkPeptides Research Database. "Durability of Linear Small-Intestinal Growth Following Treat..." RPEP-05444. Retrieved from https://rethinkpeptides.com/research/hinchliffe-2021-durability-of-linear-smallintestinal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.